Search
Chloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedIt is no longer considered useful as an anti-anxiety medication. … The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments.
Hyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … [A228423] Research into the action of hyoscyamine in published literature dates back to 1826.
Mixtures: UR N-C Urinary AntisepticCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalAlthough endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalNalbuphine is the only opioid analgesic that is not a controlled substance in the United States. … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriolPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
Synonyms: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37], N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptideModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil.
Sugammadex
go.drugbank.com/drugs/DB06206ApprovedInvestigationalSugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. … Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigationalMarketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.[L15601] … [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis.
Cantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients … [A32891, A32892] Topical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant